The LIH and BIOCODEX Join Forces to Improve Cancer Treatment

• Personalized Functional Profiling (PFP)
• Precision Health
• Translational Medicine Operations Hub (TMOH)
• Cancer

The Luxembourg Institute of Health (LIH) and multinational pharmaceutical company BIOCODEX have teamed up to advance personalized medicine and improve drug development. This new partnership will use the LIH’s cutting-edge Personalized Functional Profiling (PFP) platform to test BIOCODEX’s drug candidates on patient-derived cancer models.

Developed by the Precision Medicine Technology (PMT) Unit at the LIH, the PFP platform represents a breakthrough in precision medicine for cancer patients. The platform’s innovative approach employs organoids and spheroids—sophisticated miniature cellular models of tumors—to predict and evaluate treatment responses under various tumor conditions.

With this new collaboration, we aim to bridge the gap between the lab and real-world medical treatments. By using patient-derived models in early drug testing, we will make preclinical studies more relevant and advance better, more targeted therapies for cancer patients,

said Dr. Yong-Jun Kwon, head of the PMT Unit at the LIH.

Dr. Victoria El Khoury, a leading scientist in the PMT Unit, spearheads the platform’s implementation, focusing on developing more accurate preclinical models that enhance drug development and refine clinical trials. This work is crucial in establishing a more efficient pathway towards practical medical applications.

The partnership exemplifies the growing importance of collaboration between public research institutions and private pharmaceutical companies in advancing medical science. By combining the advanced research capabilities of the LIH with the pharmaceutical expertise of BIOCODEX, the partnership aims to accelerate the development of more effective, personalized cancer treatments.